Why the study?
Does primary metabolic and bariatric surgery reduce major adverse cardiovascular events compared to GLP-1 receptor agonist treatment in patients with type-2 diabetes?
Does primary metabolic and bariatric surgery reduce major adverse cardiovascular events compared to GLP-1 receptor agonist treatment in patients with type-2 diabetes?
In patients with type-2 diabetes, metabolic and bariatric surgery may offer superior cardiovascular protection compared to early GLP-1 receptor agonist therapy.
May support surgery preference over early GLP-1 agonists for MACE reduction in T2D; leaves open confirmation by randomized trials.
In this matched cohort study, MBS was associated with lower risk for MACE compared to treatment with early GLP-1 RA in patients with T2D.
No takes yet. Share an insight, caveat, or question.
Stenberg et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on GLP-1 agonists cardiovascular outcomesMore from International Journal of Obesity